Quebec is proposing to move medications containing diphenhydramine \u2014 the active sedating ingredient in Benadryl and related antihistamines \u2014 from open pharmacy shelves to behind-the-counter storage, a change that would require pharmacists to document every sale in a patient’s file. The proposal, published as a draft regulation in the Gazette officielle du Qu\u00e9bec<\/em> and currently open for public consultation, stops short of requiring a prescription. But it represents a meaningful tightening of controls on a substance that a provincial coroner has called dangerously under-regulated. The measure flows directly from a 2023 inquest into the overdose death of an 18-year-old in St-Mathias-sur-Richelieu \u2014 and it raises a question that the coroner himself could not answer: why did it take this long?<\/p>\n<\/p>\n On the morning of December 11, 2023, the young man’s mother found him unconscious in his bed. Toxicological analysis confirmed a lethal concentration of diphenhydramine in his blood. Coroner Vincent Denault, reviewing the circumstances, was unambiguous in his frustration. “I cannot understand why the sale of diphenhydramine is not better controlled,” he wrote in his findings. He pointed to a specific inconsistency that is difficult to dismiss: Gravol, another over-the-counter product that also contains diphenhydramine, is already kept behind the pharmacy counter in Quebec \u2014 yet Benadryl and similar single-ingredient formulations remained freely available on open shelves. That regulatory gap, Denault concluded, is indefensible given what science already knows about the drug’s toxicity.<\/p>\n<\/p>\n Denault was not breaking new ground. He noted that he had already contributed to three previous Quebec coroner investigations involving diphenhydramine fatalities. The drug has a documented history of misuse: it produces euphoric and hallucinogenic effects at high doses, and the scientific literature confirms it has been used both recreationally and in suicide attempts. A particular spike in poisonings occurred around 2020, when a so-called “Benadryl challenge” circulated on TikTok, encouraging users to consume dangerous quantities of the medication. “The deaths of children have put a face to this dangerous trend,” Denault wrote \u2014 a phrase that carries weight precisely because it is not hyperbole.<\/p>\n<\/p>\n The draft regulation, if adopted, would not make diphenhydramine a prescription drug. Patients could still obtain it without seeing a physician. What would change is the architecture of access. Pharmacists would be required to keep the product behind the counter, engage directly with the person purchasing it, record the sale in that person’s pharmaceutical file, and conduct a basic pharmacological review of that file. These are modest procedural steps, but they matter. Behind-the-counter status introduces a human interaction \u2014 a moment of professional judgment \u2014 between a potentially vulnerable person and a substance that can kill at doses not far above the therapeutic range.<\/p>\n<\/p>\n The recommendation Denault made to the provincial office of professions was precisely this: classify diphenhydramine intended for oral administration in a regulatory category that demands more active pharmacist management. Quebec’s proposed regulation appears to implement that recommendation directly. The consultation process now underway gives the public, health professionals, and industry stakeholders an opportunity to weigh in before the rule is finalized. That process is appropriate. Regulatory changes affecting access to widely used medications deserve scrutiny, and the concerns of patients who rely on these products for legitimate purposes \u2014 managing allergies, treating insomnia \u2014 deserve to be heard.<\/p>\n<\/p>\n Quebec’s move reflects something important about how provincial governments can exercise their jurisdiction over pharmacy regulation in ways that respond to genuine public health evidence. The province is not waiting for a federal reclassification of diphenhydramine. It is using the tools available to it \u2014 the regulatory authority of the Ordre des pharmaciens and the provincial professions framework \u2014 to close a gap that has already cost lives. Whether other provinces will follow, or whether Health Canada will eventually act at the national level, remains to be seen. What is clear is that the status quo \u2014 open-shelf availability of a substance with a documented lethal threshold, a history of misuse, and a pattern of preventable deaths \u2014 was never a neutral policy choice. It was an oversight. Quebec appears ready to correct it.<\/p>","protected":false},"excerpt":{"rendered":" A Death That Demanded a Response Quebec is proposing to move medications containing diphenhydramine \u2014 the active sedating ingredient in Benadryl and related antihistamines \u2014 from open pharmacy shelves to behind-the-counter storage, a change that would require pharmacists to document every sale in a patient’s file. The proposal, published as a draft regulation in the […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46,37],"tags":[],"class_list":["post-1245","post","type-post","status-publish","format-standard","category-canada","category-news"],"yoast_head":"\nThe Case That Prompted the Regulation<\/h2>\n<\/p>\n
What the Proposed Regulation Would Actually Change<\/h2>\n<\/p>\n
The Broader Implication<\/h2>\n<\/p>\n